As a Free StocksGuide user, you can view scores for all 6,894 stocks worldwide.
30 Analysts have issued a BeOne Medicines forecast:
30 Analysts have issued a BeOne Medicines forecast:
Mar '25 |
+/-
%
|
||
Revenue | 29,902 29,902 |
52%
52%
|
|
Gross Profit | 25,315 25,315 |
53%
53%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -2,244 -2,244 |
72%
72%
|
Net Profit | -3,165 -3,165 |
49%
49%
|
In millions CNY.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Beigene Ltd is a KY-based company operating in Biotechnology industry. BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The firm has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The firm has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. The company also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Head office | Cayman Islands |
Employees | 11,000 |
Website | www.beigene.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.